AstraZeneca, Merck Get FDA Priority Review for Lynparza in Advanced Ovarian Cancer

Date : 01/13/2020 @ 12:43PM
Source : Dow Jones News
Stock : AstraZeneca PLC (AZN)
Quote : 47.85  -1.48 (-3.00%) @ 12:59AM
After Hours
Last Trade
Last $ 47.87 ▲ 0.02 (0.04%)

AstraZeneca, Merck Get FDA Priority Review for Lynparza in Advanced Ovarian Cancer

Merck (NYSE:MRK)
Historical Stock Chart

2 Months : From Dec 2019 to Feb 2020

Click Here for more Merck Charts.

By Colin Kellaher


AstraZeneca PLC (AZN, AZN.LN) and Merck & Co. (MRK) Monday said the U.S. Food and Drug Administration accepted and granted priority review to a supplemental new-drug application for Lynparza in combination with bevacizumab in advanced ovarian cancer.

The drugmakers said the filing covers the maintenance treatment of women with advanced ovarian cancer whose disease showed a complete or partial response to first-line treatment with platinum-based chemotherapy and bevacizumab.

The FDA grants priority review to medicines that have the potential to provide significant improvements in the treatment of a serious disease, and the designation shortens the review period.

AstraZeneca and Merck, which in 2017 formed a collaboration to co-develop and co-commercialize AstraZeneca's Lynparza for multiple cancer types, said the agency has set a target action date for the second quarter.


Write to Colin Kellaher at


(END) Dow Jones Newswires

January 13, 2020 07:28 ET (12:28 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Latest AZN Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.